BACKGROUND AND PURPOSE: Delayed cerebral ischemia (DCI) is a major complication after aneurysmal subarachnoid hemorrhage (aSAH); it is manifested by changes in cerebral blood flow accompanied by neurological decline, and it results in long-term functional and neuropsychological impairment. Preclinical evidence has demonstrated that the arachidonic acid metabolite, 20-hydroxyeicosatetraenoic acid (20-HETE), affects cerebral microvascular tone and cerebral blood flow after aSAH. The purpose of this study was to determine whether cerebrospinal fluid 20-HETE levels were associated with DCI and long-term neuropsychological outcomes in aSAH patients. METHODS: Cerebrospinal fluid samples were collected twice daily through 14 days after hemorrhage on 108 acute, adult, aSAH patients. Samples were analyzed for 20-HETE via HPLC MSQ single quadrupole mass spectrometry. DCI was defined as the presence of impaired cerebral blood flow (angiographic vasospasm, elevated transcranial Dopplers, abnormal computed tomography or magnetic resonance perfusion scans) accompanied by neurological deterioration. Outcomes, including death and neuropsychological testing, were completed at 3 months after hemorrhage. RESULTS: Detectable 20-HETE levels were observed in 31% of patient samples and were associated with severity of hemorrhage (Hunt & Hess [HH], P=0.04; Fisher, P=0.05). Detection of 20-HETE was not associated with angiographic vasospasm (P=0.34); however, detectable 20-HETE was significantly associated with DCI (P=0.016). Our data also suggest that detectable 20-HETE was associated with decreased performance in 5 neuropsychological domains. CONCLUSIONS: These results provide the first clinical evidence that cerebrospinal fluid 20-HETE concentrations are associated with DCI and poor outcomes, and this provides impetus for future studies to elucidate the clinical utility of inhibiting 20-HETE formation as a novel therapeutic intervention in patients with aSAH.
BACKGROUND AND PURPOSE:Delayed cerebral ischemia (DCI) is a major complication after aneurysmal subarachnoid hemorrhage (aSAH); it is manifested by changes in cerebral blood flow accompanied by neurological decline, and it results in long-term functional and neuropsychological impairment. Preclinical evidence has demonstrated that the arachidonic acid metabolite, 20-hydroxyeicosatetraenoic acid (20-HETE), affects cerebral microvascular tone and cerebral blood flow after aSAH. The purpose of this study was to determine whether cerebrospinal fluid 20-HETE levels were associated with DCI and long-term neuropsychological outcomes in aSAH patients. METHODS: Cerebrospinal fluid samples were collected twice daily through 14 days after hemorrhage on 108 acute, adult, aSAH patients. Samples were analyzed for 20-HETE via HPLC MSQ single quadrupole mass spectrometry. DCI was defined as the presence of impaired cerebral blood flow (angiographic vasospasm, elevated transcranial Dopplers, abnormal computed tomography or magnetic resonance perfusion scans) accompanied by neurological deterioration. Outcomes, including death and neuropsychological testing, were completed at 3 months after hemorrhage. RESULTS: Detectable 20-HETE levels were observed in 31% of patient samples and were associated with severity of hemorrhage (Hunt & Hess [HH], P=0.04; Fisher, P=0.05). Detection of 20-HETE was not associated with angiographic vasospasm (P=0.34); however, detectable 20-HETE was significantly associated with DCI (P=0.016). Our data also suggest that detectable 20-HETE was associated with decreased performance in 5 neuropsychological domains. CONCLUSIONS: These results provide the first clinical evidence that cerebrospinal fluid 20-HETE concentrations are associated with DCI and poor outcomes, and this provides impetus for future studies to elucidate the clinical utility of inhibiting 20-HETE formation as a novel therapeutic intervention in patients with aSAH.
Authors: A J Saykin; R C Gur; R E Gur; D L Shtasel; K A Flannery; L H Mozley; B L Malamut; B Watson; P D Mozley Journal: Appl Neuropsychol Date: 1995-05
Authors: James V Gainer; Aouatef Bellamine; Elliott P Dawson; Kristie E Womble; Sarah W Grant; Yarong Wang; L Adrienne Cupples; Chao-Yu Guo; Serkalem Demissie; Christopher J O'Donnell; Nancy J Brown; Michael R Waterman; Jorge H Capdevila Journal: Circulation Date: 2004-12-20 Impact factor: 29.690
Authors: Samuel M Poloyac; Yuqing Zhang; Robert R Bies; Patrick M Kochanek; Steven H Graham Journal: J Cereb Blood Flow Metab Date: 2006-03-29 Impact factor: 6.200
Authors: Natalie C Ward; I-Jung Tsai; Anne Barden; Frank M van Bockxmeer; Ian B Puddey; Jonathan M Hodgson; Kevin D Croft Journal: Hypertension Date: 2008-04-07 Impact factor: 10.190
Authors: Jonathan W Nelson; Jennifer M Young; Rohan N Borkar; Randy L Woltjer; Joseph F Quinn; Lisa C Silbert; Marjorie R Grafe; Nabil J Alkayed Journal: Prostaglandins Other Lipid Mediat Date: 2014-09-30 Impact factor: 3.072
Authors: Mark K Donnelly; Elizabeth A Crago; Yvette P Conley; Jeffery R Balzer; Dianxu Ren; Andrew F Ducruet; Patrick M Kochanek; Paula R Sherwood; Samuel M Poloyac Journal: J Cereb Blood Flow Metab Date: 2015-04-29 Impact factor: 6.200
Authors: Matthew Gallek; Sheila Alexander; Elizabeth Crago; Paula Sherwood; Michael Horowitz; Samuel Poloyac; Yvette Conley Journal: Biol Res Nurs Date: 2012-09-19 Impact factor: 2.522
Authors: Dominic A Siler; Ross P Martini; Jonathan P Ward; Jonathan W Nelson; Rohan N Borkar; Kristen L Zuloaga; Jesse J Liu; Stacy L Fairbanks; Jeffrey S Raskin; Valerie C Anderson; Aclan Dogan; Ruikang K Wang; Nabil J Alkayed; Justin S Cetas Journal: Neurocrit Care Date: 2015-04 Impact factor: 3.210
Authors: Mark K Donnelly; Yvette P Conley; Elizabeth A Crago; Dianxu Ren; Paula R Sherwood; Jeffery R Balzer; Samuel M Poloyac Journal: J Cereb Blood Flow Metab Date: 2014-11-12 Impact factor: 6.200
Authors: Sebastian Major; Gabor C Petzold; Clemens Reiffurth; Olaf Windmüller; Marco Foddis; Ute Lindauer; Eun-Jeung Kang; Jens P Dreier Journal: J Cereb Blood Flow Metab Date: 2016-01-01 Impact factor: 6.200